Iron Dextran
DrugSingle intravenous infusion of iron dextran 1000mg.
Other names: Experimental
NCT Number: NCT03438227
Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. While treatment of iron-deficiency anemia with iron supplementation is recommended, treatment strategies remain controversial: the American College of Obstetrics and Gynecology recommends oral iron supplementation with parental iron reserved for the rare patient who cannot tolerate or will not take oral iron, while United Kingdom professional organizations recommend a more liberal use of parenteral iron. The reason for these disparate recommendations is that few high-quality studies comparing oral to parenteral iron have been conducted in developed countries, and the potential impact of parental iron treatment on obstetric and perinatal outcomes remains unclear. We propose the first randomized-controlled trial in the United States describing the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron.
Looking for future studies?
Notify MeFemale
Interventional
Phase 4
Indiana University School of Medicine, Indianapolis, Indiana, United States
Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. In the United States, anemia affects nearly 20% of pregnancies and the majority is iron-deficiency anemia. Therefore, treatment of iron-deficiency anemia with iron supplementation is recommended.1 However, there is controversy about the treatment strategies.
The American College of Obstetrics and Gynecology recommends oral iron supplementation for iron-deficiency anemia in pregnancy, with parental iron reserved only for the "rare patient who cannot tolerate or will not take oral iron" (1) Conversely, guidelines from the United Kingdom. are more liberal on the use of parental iron for the treatment of iron-deficiency anemia in pregnancy (2). Both treatment guidelines are based on limited data regarding the risks and benefits of parental iron for treatment of iron-deficiency anemia in pregnancy. The majority of randomized trials were conducted in developing country settings. In fact, few high-quality studies have been conducted in developed countries, and none has been conducted in the United States Moreover, there is limited data from prior studies on the impact of parental iron treatment on perinatal outcomes. The most recent Cochrane review including mostly from trials conducted in low-income countries found that, although parenteral iron improved hemoglobin levels and iron stores than the oral route, no clinical outcomes were assessed and there were insufficient data on adverse effects (3). The authors concluded that "large, good quality trials, assessing clinical outcomes including adverse effects … are required" (3).
This randomized controlled trial aims to assess the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron. We hypothesize that treating iron-deficiency anemia with parental iron is associated with improved maternal and neonatal outcomes compared with a protocol based on oral iron. To increase generalizability of the findings, we will use broad inclusion criteria and analyze data using the intention-to-treat principle.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single intravenous infusion of iron dextran 1000mg.
Other names: Experimental
Oral iron supplementation with ferrous sulfate 325mg one to three times daily
Other names: Active comparator
Time frame: At delivery
Number of participants with maternal hemoglobin <11g/dl at delivery
Time frame: On admission to inpatient obstetrics unit for delivery
Maternal hemoglobin on admission to inpatient obstetrics unit for delivery
Time frame: 2 - 3 days after single intravenous iron infusion or initiation of oral iron
Participants reporting symptoms when contacted by via telephone 2 - 3 days after their infusion of intravenous iron or initiation of oral iron
Time frame: At delivery
Number of participants with hemoglobin below 10g/dl at delivery
Time frame: At delivery
Maternal serum ferritin level in μg/L at delivery
Time frame: During inpatient admission for delivery of neonate
Participant receiving transfusion of packed red blood cells during admission for delivery of infant obtained via medical chart review.
Time frame: Once, at infant delivery
Whether infant was delivered vaginally or via cesarean section
Time frame: Once, at infant delivery
Gestational age in weeks at delivery
Time frame: Obtained once, at infant delivery
Neonatal weight at delivery
Time frame: Drawn once from umbilical cord segment at delivery
Umbilical cord arterial pH obtained at delivery
Time frame: Obtained at 1 minute of life
The APGAR score, named after the Virginia Apgar, pediatrician who came up with it, measures the physical condition of a newborn infant on a scale ranging from a minimum of 0 (worsts) to a maximum of 10 (best).
Time frame: Drawn once from umbilical cord segment at birth
Neonatal hemoglobin in g/dl at delivery
Time frame: At birth
Neonatal morbidity composite, defined by the occurrence of one or more of the following neonatal morbidities: neonatal seizures (diagnosed by clinician), intraventricular hemorrhage (diagnosed by clinician on brain MRI or Ultrasound), hypoxic-ischemic encephalopathy (diagnosed by clinician), neonatal hypothermic therapy (brain cooling as documented on inpatient record, sepsis (diagnosed by blood culture), respiratory distress syndrome (diagnosed by clinician), hyperbilirubinemia requiring photo therapy (diagnosed by clinician), birth injury (diagnosed by clinician), or meconium aspiration syndrome (diagnosed by clinician), neonatal intensive care unit admission (documented in the inpatient record).
Time frame: Drawn once from umbilical cord segment at birth
Neonatal ferritin in ug/L at delivery
Indiana University
Other
Acronym: IVIDA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07648628
Anemia, Anemia, Postpartum
Delhi, India
View Trial DetailsNCT05545527
Anemia, Anemia, Hypochromic
Belagavi, Karnataka, India
View Trial DetailsNCT04074707
Iron Deficiency Anemia of Pregnancy
Salaya, Changwat Nakhon Pathom, Thailand
View Trial DetailsNCT03961074
Anemia, Anemia, Hypochromic
Beijing, Beijing Municipality, China
View Trial Details